Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CONTINUOUS COMBINED AND SEQUENTIAL ESTRADIOL AND NORETHINDRONE ACETATE TREATMENT OF POSTMENOPAUSAL WOMEN - EFFECT ON PLASMA-LIPOPROTEINS INA 2-YEAR PLACEBO-CONTROLLED TRIAL
Autore:
MUNKJENSEN N; ULRICH LG; OBEL EB; NIELSEN SP; EDWARDS D; MEINERTZ H;
Indirizzi:
UNIV COPENHAGEN HOSP,RIGSHOSP,DEPT MED B,LIPID & NUTR LAB,AMAGERBROGADE 242 DK-2300 COPENHAGEN S DENMARK CENT HOSP HILLEROD,DEPT OBSTET & GYNECOL HILLEROD DENMARK CENT HOSP HILLEROD,DEPT CLIN PHYSIOL & NUCL MED HILLEROD DENMARK NOVO NORDISK AS,DEPT MED,DIV PHARMACEUT DK-2880 BAGSVAERD DENMARK
Titolo Testata:
American journal of obstetrics and gynecology
fascicolo: 1, volume: 171, anno: 1994,
pagine: 132 - 138
SICI:
0002-9378(1994)171:1<132:CCASEA>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; REPLACEMENT THERAPY; RISK-FACTORS; ESTROGEN REPLACEMENT; CHOLESTEROL; PROGESTOGEN; ATHEROSCLEROSIS; SUBFRACTIONS; METABOLISM; REGRESSION;
Keywords:
MENOPAUSE; PLASMA LIPOPROTEINS; PLASMA LIPIDS; POSTMENOPAUSAL ESTROGEN-PROGESTOGEN REPLACEMENT THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
N. Munkjensen et al., "CONTINUOUS COMBINED AND SEQUENTIAL ESTRADIOL AND NORETHINDRONE ACETATE TREATMENT OF POSTMENOPAUSAL WOMEN - EFFECT ON PLASMA-LIPOPROTEINS INA 2-YEAR PLACEBO-CONTROLLED TRIAL", American journal of obstetrics and gynecology, 171(1), 1994, pp. 132-138

Abstract

OBJECTIVE: Our purpose was to examine the effects of postmenopausal estrogen therapy supplemented with progestogen on plasma lipoprotein levels. STUDY DESIGN: One hundred thirteen women were randomized to receive either placebo or a combination of 17 beta-estradiol and norethindrone acetate administered continuously (Kliogest) or sequentially (Trisequens). Plasma lipoprotein levels were measured at baseline and after 2 years of treatment and compared by analysis of variance. RESULTS: Hormone therapy lowered plasma cholesterol levels (p < 0.001) and low-density lipoprotein cholesterol (Kliogest, p < 0.001; Trisequens, p < 0.01), whereas high-density lipoprotein cholesterol levels were unchanged (Trisequens) or reduced (Kliogest, p < 0.01), primarily because ofa decrease in the high-density lipoprotein-2 subfraction (p < 0.05). Low-density lipoprotein/high-density lipoprotein cholesterol ratios remained unchanged. CONCLUSIONS: Although hormonal replacement therapy with estradiol combined with norethindrone acetate eliminated the increase in high-density lipoprotein cholesterol levels observed with estrogen monotherapy, the reductions in low-density lipoprotein cholesterolconcentrations still suggest reduced cardiovascular risk, according to the National Cholesterol Education Program and to recent observations indicating that risk is not necessarily inversely proportional to high-density lipoprotein cholesterol levels.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 09:09:47